PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1558343
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1558343
According to Stratistics MRC, the Global mHealth Apps Market is accounted for $37.8 billion in 2024 and is expected to reach $96.6 billion by 2030 growing at a CAGR of 16.9% during the forecast period. mHealth Apps are mobile applications that support healthcare services and information. They offer various health-related functionalities, such as health data collection, disease management, health education, telemedicine, and health monitoring. Benefits of mHealth apps include increased accessibility, improved patient engagement, enhanced convenience, and cost-effectiveness. These apps help manage chronic conditions, provide health education, enable remote consultations, and track fitness goals. They also reduce the need for in-person healthcare visits.
According to the Mobile Economy 2023 report, smartphone penetration was at 76% in 2022 and is predicted to reach 92% by 2030.
Increased demand for health monitoring
The increasing prevalence of chronic diseases like diabetes, hypertension, and heart disease necessitates continuous health monitoring through mHealth apps. These tools help patients track vital signs, manage symptoms, and manage treatment more effectively. Preventive healthcare is also gaining importance, with mHealth apps tracking fitness, nutrition, sleep, and overall wellness.
Attractive targets for cyber threats
mHealth apps are vulnerable to cybercriminals, leading to unauthorized access to personal health information (PHI), identity theft, financial loss, and privacy violations. Cyberattacks can compromise health data integrity, causing manipulated clinical measurements, misdiagnoses, and inappropriate treatments. Victims may experience anxiety, trauma, and vulnerability, which can exacerbate existing mental health conditions. Therefore, mHealth apps must be vigilant to protect sensitive health data.
Increase in mobile subscriptions and internet penetration
mHealth apps have expanded their reach, reaching underserved populations in rural areas. This accessibility allows for real-time remote patient monitoring, improving care quality and facilitating timely interventions. The proliferation of smartphones and internet access has led to a surge in mHealth app downloads, reaching 3.7 billion, indicating significant revenue growth in the digital health sector. This growth in usage is particularly beneficial for chronic disease management.
Technological barriers in developing regions
The digital divide and unequal distribution of devices and connectivity in developing regions hinder the widespread use of mobile health apps, limiting their potential user base and market growth. This raises concerns about equitable healthcare delivery. Additionally, inadequate health system readiness and lack of interoperability between mHealth apps and existing healthcare systems further hinder adoption. These challenges contribute to the digital divide and hinder the effectiveness and scalability of mHealth solutions.
Covid-19 Impact
The pandemic led to a surge in demand for remote healthcare, with mHealth apps becoming crucial for symptom tracking, telemedicine consultations, and managing chronic conditions. Governments and health organizations promoted these apps to raise awareness and encourage public adoption. The crisis altered perceptions of digital health technologies, making them more acceptable and necessary for healthcare providers and patients, potentially impacting future healthcare delivery models.
The medical apps segment is expected to be the largest during the forecast period
The medical apps is expected to be the largest during the forecast period as they aid in chronic disease management through remote monitoring, medication reminders, and health tracking. The rise in chronic conditions drives demand for mHealth solutions. Medical apps also boost user engagement by empowering users to take control of their health, leading to better health outcomes through features like telemedicine consultations and health tracking.
The chronic disease management segment is expected to have the highest CAGR during the forecast period
The chronic disease management segment is expected to have the highest CAGR during the forecast period as chronic diseases demand self-management tools like medication reminders, symptom tracking, and health data logging, leading to increased app usage and market growth. mHealth apps have expanded to include diseases like diabetes, hypertension, and cardiovascular issues, with nearly half of available apps designed for these conditions.
North America is projected to hold the largest market share during the forecast period owing to increasing mobile usage & healthcare expenditure, growing 5G networks, and rising number of government initiatives & funding are driving the regional market growth. As per the World Bank statistics, the per capita national health expenditure in North America in 2022 was about USD 11,076.74. Furthermore, rising chronic disease prevalence and increasing geriatric population in the region are expected to support market growth.
Asia Pacific is projected to witness the highest CAGR over the forecast period owing to increasing incidence of chronic & infectious diseases, rising healthcare expenditure, ineffective hospital service management, and a growing elderly population, are compelling governments & healthcare providers to develop new healthcare delivery models. For instance, in January 2024, JD Health introduced a new elderly care channel on its app to provide a comprehensive platform for the various healthcare needs of China's aging population.
Key players in the market
Some of the key players in mHealth Apps market include Abbott, AirStrip Technologies, Inc., Apple Inc, AstraZeneca, AT&T, Boston Scientific Corporation, Fitbit Inc, Google Inc., Johnson & Johnson Services, Inc., Livongo Health, Novartis AG, Omada Health, Inc., Omron Healthcare, Inc, Orange, Pfizer Inc., Qualcomm Technologies, Inc., Samsung Electronics Co. Ltd., Sanofi, Teladoc Health, Inc. and Veradigm LLC
In September 2024, Abbott announced U.S. availability of Lingo(TM), the company's first continuous glucose monitoring system available without a prescription. Lingo is based on Abbott's world-leading FreeStyle Libre(R) continuous glucose monitoring technology1, now used by more than 6 million people with diabetes globally1.
In August 2024, Abbott announced the expansion of its Pure Bliss(TM) by Similac(R) line of organic, and European-made infant formulas that give parents a variety of products to meet specific formula preferences.
In June 2024, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.